Table 2.
Demographic characteristics of patients from Cytosponge® studies. Values are numbers (percentages) unless stated otherwise
| Characteristics | All participants* | Men** | Women** |
|---|---|---|---|
| Age (years) - median (IQR) | 62 (54–68) | 63 (54–69) | 61 (54–67) |
| Missing data | 153 (6.3) | 119 (12.8) | 36 (2.4) |
| Number of participants | |||
| All studies | 2,418 (100) | 1,486 (61.5) | 932 (38.5) |
| Study 1 (BEST1 Study) | 518 (21.4) | 240 (46.3) | 278 (56.7) |
| Study 2 (BEST2 Study) | 1,498 (62.0) | 1,035 (69.1) | 463 (30.9) |
| Study 3 (BEST Study Australia) | 224 (9.3) | 95 (42.4) | 129 (57.6) |
| Study 4 (POST-RFA Study) | 76 (3.1) | 58 (76.3) | 18 (23.7) |
| Study 5 (EoE Study) | 102 (4.2) | 58 (56.9) | 44 (43.1) |
| Indication to Cytosponge® | |||
| GERD | 1,329 (55.0) | 632 (47.6) | 697 (52.4) |
| BE | 987 (40.8) | 796 (80.6) | 191 (19.4) |
| EoE | 102 (4.2) | 58 (56.9) | 44 (43.1) |
| Body Mass Index (BMI, kg/m2) | |||
| Median (IQR) | 28.2 (25.1–31.5) | 28.1 (25.6–31.0) | 28.6 (24.8–33.1) |
| Underweight (<18.5) | 14 (0.6) | 12 (85.7) | 2 (14.3) |
| Normal (18.5 to 24.9) | 447 (18.5) | 185 (41.4) | 262 (58.6) |
| Overweight (25.0 to 29.9) | 853 (35.3) | 236 (27.7) | 617 (72.3) |
| Obese (≥30.0) | 739 (30.6) | 313 (42.4) | 426 (57.6) |
| Missing data | 365 (15.0) | 186 (51.0) | 179 (49.0) |
| Waist to Hip Ratio*** | |||
| Median (IQR) | 0.93 (0.87–0.98) | 0.96 (0.92–0.99) | 0.86 (0.81–0.91) |
| Low Risk | 786 (32.5) | 622 (79.1) | 164 (20.9) |
| Moderate Risk | 558 (23.1) | 379 (67.9) | 179 (32.1) |
| High Risk | 626 (25.9) | 244 (39.0) | 382 (61.0) |
| Missing data | 448 (18.5) | 241 (53.8) | 207 (46.2) |
| Smoking Status | |||
| Never | 809 (33.5) | 466 (57.6) | 343 (42.4) |
| Former | 971 (40.2) | 630 (64.9) | 341 (35.1) |
| Active | 191 (7.9) | 133 (69.6) | 58 (30.4) |
| Missing data | 447 (18.5) | 257 (57.5) | 190 (42.5) |
| Hiatus hernia | |||
| Present | 1,191 (49.3) | 825 (69.3) | 366 (30.7) |
| Absent | 1,025 (42.4) | 538 (52.5) | 487 (47.5) |
| Missing data | 202 (8.3) | 123 (60.9) | 79 (39.1) |
| Previous endoscopic treatment (EMR, RFA, PDT) | |||
| Yes | 243 (10.0) | 204 (84.0) | 39 (16.0) |
| No | 2,175 (90.0) | 1,282 (58.9) | 893 (41.1) |
EMR, endoscopic mucosal resection; PDT, photo-dynamic therapy; RFA, radiofrequency ablation
*
The proportion (%) of patients from each group in the first column refers to the total participant number
**
The proportion (%) of male and female patients refers to the number of participants from each group (first row), not the total participant number
***
Waist to hip ratio was considered low risk for male <0.95 and female <0.80, moderate risk for male 0.95–1, female 0.81–0.85 and high risk for male >1, female >0.85